BR9708815B1 - compostos úteis para prevenção e tratamento de desordens do sistema nervoso central. - Google Patents

compostos úteis para prevenção e tratamento de desordens do sistema nervoso central.

Info

Publication number
BR9708815B1
BR9708815B1 BRPI9708815-3A BR9708815A BR9708815B1 BR 9708815 B1 BR9708815 B1 BR 9708815B1 BR 9708815 A BR9708815 A BR 9708815A BR 9708815 B1 BR9708815 B1 BR 9708815B1
Authority
BR
Brazil
Prior art keywords
nervous system
central nervous
system disorders
prevention
treatment
Prior art date
Application number
BRPI9708815-3A
Other languages
English (en)
Portuguese (pt)
Other versions
BR9708815A (pt
Inventor
William Scott Caldwell
Gary Maurice Dull
Grayland Page Dobson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24532629&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9708815(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of BR9708815A publication Critical patent/BR9708815A/pt
Publication of BR9708815B1 publication Critical patent/BR9708815B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI9708815-3A 1996-04-23 1997-04-16 compostos úteis para prevenção e tratamento de desordens do sistema nervoso central. BR9708815B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63176196A 1996-04-23 1996-04-23
PCT/US1997/006398 WO1997040011A1 (en) 1996-04-23 1997-04-16 Pharmaceutical compositions for prevention and treatment of central nervous system disorders

Publications (2)

Publication Number Publication Date
BR9708815A BR9708815A (pt) 2000-01-04
BR9708815B1 true BR9708815B1 (pt) 2009-01-13

Family

ID=24532629

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9708815-3A BR9708815B1 (pt) 1996-04-23 1997-04-16 compostos úteis para prevenção e tratamento de desordens do sistema nervoso central.

Country Status (12)

Country Link
US (2) US6603011B1 (enExample)
EP (2) EP0900200B9 (enExample)
JP (2) JP4357001B2 (enExample)
AT (1) ATE416164T1 (enExample)
AU (1) AU727976B2 (enExample)
BR (1) BR9708815B1 (enExample)
CA (1) CA2252515C (enExample)
DE (1) DE69739142D1 (enExample)
DK (1) DK0900200T5 (enExample)
ES (1) ES2318856T4 (enExample)
PT (1) PT900200E (enExample)
WO (1) WO1997040011A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6979695B2 (en) * 1996-04-23 2005-12-27 Targacept, Inc. Compounds capable of activating cholinergic receptors
US20020052497A1 (en) 2000-03-09 2002-05-02 Targacept, Inc. Compounds capable of activating cholinergic receptors
US6166048A (en) * 1999-04-20 2000-12-26 Targacept, Inc. Pharmaceutical compositions for inhibition of cytokine production and secretion
EP1068186A2 (en) 1998-04-02 2001-01-17 Targacept, Inc. Pharmaceutical compositions and methods for use
US7790757B2 (en) * 1998-06-16 2010-09-07 Targacept, Inc. Compounds capable of activating cholinergic receptors
EP1086082B9 (en) * 1998-06-16 2005-03-02 Targacept, Inc. Arylsubstituted olefinic amines and their use as cholinergic receptors agonists
US6232316B1 (en) 1998-06-16 2001-05-15 Targacept, Inc. Methods for treatment of CNS disorders
US20050131034A1 (en) 1998-06-16 2005-06-16 Caldwell William S. Compounds capable of activating cholinergic receptors
US6455734B1 (en) 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
AU2005201609B2 (en) * 1999-04-20 2007-10-18 Targacept, Inc Pharmaceutical compositions for inhibition of cytokine production and secretion
US20010031771A1 (en) 1999-05-24 2001-10-18 Gary Maurice Dull Pharmaceutical compositions and methods for use
CA2376061A1 (en) * 1999-06-07 2000-12-14 Targacept, Inc. Pharmaceutical compositions and methods for use
MXPA02001095A (es) * 1999-07-30 2002-08-20 Vertex Pharma Derivados de amina ciclicos y aciclicos.
AU2001257449A1 (en) * 2000-05-01 2001-11-12 Targacept, Inc. Imaging of nicotinic acetylcholine receptor subtypes
FR2838436A1 (fr) * 2002-04-16 2003-10-17 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
WO2003095415A2 (fr) * 2002-04-16 2003-11-20 Rhodia Chimie Composes amines porteurs d'au moins un allyle et d'un difluoromethylene et et leur preparation
FR2847578A1 (fr) * 2002-11-21 2004-05-28 Rhodia Chimie Sa Composes amines porteurs d'au moins un allyle et d'un difluoromethyle et procede utile a leur synthese
BRPI0418712B8 (pt) * 2004-04-02 2021-06-22 Arterial Remodelling Tech Inc método para preparar uma montagem para fornecimento de um stent polimérico degradável e bioreabsorvível, montagem para fornecer um stent degradável e bioreabsorvível e método para preparar um stent polimérico degradável e bioreabsorvível
US7459469B2 (en) 2004-11-10 2008-12-02 Targacept, Inc. Hydroxybenzoate salts of metanicotine compounds
UA88792C2 (ru) 2004-11-10 2009-11-25 Таргасепт, Інк. Гидроксибензоатные соли метаникотиновых соединений
EP2021325A2 (en) 2006-05-09 2009-02-11 AstraZeneca AB Salt forms of (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]-4-penten-2-amine
TWI389889B (zh) 2006-05-09 2013-03-21 Targacept Inc （２ｓ）-（４ｅ）-ｎ-甲基-５-〔３-（５-異丙氧基吡啶）基〕-４-戊烯-２-胺之新穎多晶型
AR062860A1 (es) * 2006-09-15 2008-12-10 Astrazeneca Ab Combinaciones terapeuticas 482
WO2008091588A1 (en) * 2007-01-22 2008-07-31 Targacept, Inc. Intranasal, buccal, and sublingual administration of metanicotine analogs
WO2009140201A1 (en) * 2008-05-12 2009-11-19 Targacept, Inc. Methods for preventing the development of retinopathy by the oral administration of nnr ligands
WO2010080757A2 (en) 2009-01-07 2010-07-15 Astrazeneca Ab Combinations with an alpha-4beta-2 nicotinic agonist
CN103180277A (zh) 2010-05-20 2013-06-26 塔格塞普特股份有限公司 制备芳基取代的烯属胺的新方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4965074A (en) 1985-03-05 1990-10-23 Ciba-Geigy Corporation Method of treating memory impairment
US4684654A (en) * 1985-08-14 1987-08-04 American Cyanamid Company 3-heteroalkyl-2,4-quinzaolinediones
US4927838A (en) * 1987-07-10 1990-05-22 Hoffman-La Roche Inc. Pyridine compounds which are useful in treating a disease state characterized by an excess of platelet activating factors
US4788206A (en) * 1987-07-10 1988-11-29 Hoffmann-La Roche Inc. Pentadieneamides
US4786646A (en) * 1987-07-10 1988-11-22 Hoffmann-La Roche Inc. Cyclopropylpropenamides
US4922901A (en) 1988-09-08 1990-05-08 R. J. Reynolds Tobacco Company Drug delivery articles utilizing electrical energy
US5210076A (en) 1988-09-13 1993-05-11 Berliner David L Methods of treating Parkinson's disease using melanin
US5356906A (en) 1989-10-27 1994-10-18 The Du Pont Merck Pharmaceutical Company (N-phthalimidoalkyl) piperidines useful as treatments for psychosis
DE4102289A1 (de) 1991-01-26 1992-07-30 Bayer Ag Verfahren zur herstellung von (hetero)arylalk(en/in)-ylaminen und neue (hetero)arylkinylamine
DK0588917T3 (da) 1991-05-29 2001-02-12 Abbott Lab Isoxazol- og isothiazolforbindelser, som forstærker kognitiv funktion
US5212188A (en) 1992-03-02 1993-05-18 R. J. Reynolds Tabacco Company Method for treatment of neurodegenerative diseases
US5242935A (en) 1992-03-06 1993-09-07 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5227391A (en) 1992-04-10 1993-07-13 R. J. Reynolds Tobacco Company Method for treatment of neurodegenerative diseases
US5723477A (en) 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
ATE334120T1 (de) * 1995-01-06 2006-08-15 Targacept Inc Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
US5616707A (en) 1995-01-06 1997-04-01 Crooks; Peter A. Compounds which are useful for prevention and treatment of central nervous system disorders
US5616716A (en) * 1996-01-06 1997-04-01 Dull; Gary M. (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds

Also Published As

Publication number Publication date
JP2008247903A (ja) 2008-10-16
PT900200E (pt) 2009-02-26
ES2318856T4 (es) 2010-03-03
EP0900200B1 (en) 2008-12-03
DK0900200T5 (da) 2010-01-11
ES2318856T3 (es) 2009-05-01
US6555684B2 (en) 2003-04-29
EP0900200B9 (en) 2009-10-21
BR9708815A (pt) 2000-01-04
CA2252515C (en) 2006-11-07
WO1997040011A1 (en) 1997-10-30
JP2000509041A (ja) 2000-07-18
DE69739142D1 (de) 2009-01-15
EP1997806A1 (en) 2008-12-03
CA2252515A1 (en) 1997-10-30
EP0900200A1 (en) 1999-03-10
AU2733297A (en) 1997-11-12
AU727976B2 (en) 2001-01-04
DK0900200T3 (da) 2009-03-30
US6603011B1 (en) 2003-08-05
JP4357001B2 (ja) 2009-11-04
ATE416164T1 (de) 2008-12-15
US20020032206A1 (en) 2002-03-14

Similar Documents

Publication Publication Date Title
BR9708815A (pt) Composições farmacêuticas para prevenção e tratamento de desordens do sistema nervoso central.
NO912758D0 (no) Anvendelse av det virksomme stoffet flupirtin for bekjempelse av muskelspenninger.
DE68929540D1 (de) Substituierte Phenylpyrimidine Derivate, für die Behandlung oder Prevention von ZNS-Erkrankungen
UA27911C2 (uk) Засіб для лікування або запобігання фізіологічних розладів, які викликані надлишком тахікініну
DE69411424D1 (de) Zur Behandlung von Erkrankungen des Zentralnervensystems verwendbare Benzimidazole
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
ES502656A0 (es) Un procedimiento para la preparacion de nuevos derivados de 2-propanol
DE60112766D1 (de) Verwendung von derivaten der valproinsäureamide und 2-valproinsäureamid zur behandlung und prävention von schmerzen und/oder kopfschmerzen
ATE334120T1 (de) Pharmazeutische zusammensetzungen zur vorbeugung und behandlung von störungen des zentralnervensystems
DE69837322D1 (de) Verfahren zur therapeutischen verabreichung von anti-cd40l-mitteln
DE3687097D1 (de) Therapeutisches mittel zur behandlung haematopoietischer krankheiten.
DE69300321D1 (de) Behandlung neurodegenerativer Erkrankungen.
DE3681690D1 (de) N-substituierte 3-piperidin- oder 3-pyridincarbonsaeuren und deren derivate.
ATE142499T1 (de) Verwendung von kreatinphosphat oder phosphoenolbrenztraubensäure zur behandlung von tumoren
DE59209728D1 (de) VERWENDUNG VON ANTAGONISTEN ODER PARTIELLEN AGONISTEN AM 5-HT 1a-REZEPTOR ZUR BEHANDLUNG UND PRÄVENTION VON KOGNITIVEN STÖRUNGEN
DK0845988T3 (da) Hidtil ukendte kondenserede isoquinoliner som dopaminreceptorligander
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
ATE225171T1 (de) Aminosäurederivate zur behandlung von schlaganfall
ATE239470T1 (de) Melatonin-derivate zur verwendung in der behandlung von desynchronisierungs-erkankungen
ATE285773T1 (de) Pharmazeutische zusammensetzungen zur behandlung von neurologischen krankheiten
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
ES1022449Y (es) Aparato terapeutica para tratamiento de sintomas ocasionados por enfermedades.
EP1056458A4 (en) PROCESS FOR THE TREATMENT OF PAIN, ESPECIALLY CHRONIC PAIN SPECIFIC TO WOMEN
DE69314413D1 (de) Piperidino-3,4-dihydrocarbostyryl Verbindungen zur Behandlung von ischämischen Störungen
DE69827706D1 (de) 5-(Heteroaryl)alkyl)-3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid (PBI) Derivate zur Behandlung von Störungen des zentralen Nervensystems

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B25A Requested transfer of rights approved

Free format text: TARGACEPT, INC. (US)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL.7: C07D 213/38, A61K 31/44, A61P 25/00

Ipc: C07D 213/38, A61K 31/44, A61P 25/00

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 07/04/2009, OBSERVADAS AS CONDICOES LEGAIS.

B22O Other matters related to patents and certificates of addition of invention: legal action concerning patent

Free format text: INPI-52400.061595/2013 ORIGEM: JUIZO DA 013A VARA FEDERAL DO RIO DE JANEIRO PROCESSO NO 0132277-54.2013.4.02.5101 ACAO DE NULIDADE DAS PATENTES SUBMETIDAS AO MAILBOX (ART. 229, PARAGRAFO UNICO DA LPI); ALTERNATIVAMENTE, A DECRETACAO DA NULIDADE PARCIAL PARA CORRECAO DO PRAZO DE VIGENCIA; SUBSIDIARIAMENTE, CASO SE ENTENDA NAO SER O CASO DE NULIDADE, A CORRECAO DO ATO ADMINISTRATIVO PARA ADEQUACAO DA VIGENCIA DAS PATENTES. AUTOR: INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL - INPI REU: SMITHKLINE BEECHAM BIOLOGICALS S.A. , SMITHKLINE BEECHAM CORPORATION, SMITHKLINE BEECHAM P.L.C, SYNGENTA PARTICIPATIONS AG, TARGACEPT, INC.

B21B Extinction acc. art. 78, item ii - on waiver by the patentee, without prejudice to the rights of third parties

Free format text: HOMOLOGADA A RENUNCIA DA PATENTE, SOLICITADA ATRAVES DO PROTOCOLO ELETRONICO WBRJ NO 860140162172 DE 24/09/2014.